Anti-PD-1 mAbs can induce sustained clinical responses in cancer but how they function in vivo remains incompletely understood. Garris et al. show that effective anti-PD-1 immunotherapy requires intratumoral dendritic cells (DCs) producing IL-12. Anti-PD-1 indirectly activates DCs through IFN-g released from drug-activated T cells. Furthermore, agonizing the non-canonical NF-kB pathway activates DCs and enhances aPD-1 therapy in an IL-12-dependent manner. Garris et al., 2018 , Immunity 49, 1148 
Currently approved immune checkpoint blockers are monoclonal antibodies that target the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1) pathways. These inhibitory pathways are important because they protect the host from uncontrolled immune activation (Keir et al., 2008) but they can also be co-opted by tumors, which make them resist immune attack (Wherry, 2011) . For instance, tumor-infiltrating cytotoxic CD8 + T cells often express PD-1 that renders them ineffective against tumors. Consequently, anti-PD-1 (aPD-1) mAbs, or anti-PDL1 mAbs, are designed to antagonize the PD-1 inhibitory pathway in T cells and potentiate CD8 + T cell-mediated tumor destruction. To date, FDA-approved therapeutics targeting the PD-1-PDL1 signaling axis, in particular aPD-1 mAbs, have proved efficacious in the clinic among immune checkpoint blockade therapies. The ability of these drugs to drive sustained tumor control depends on several variables, including tumor infiltration by CD8 + T cells (Galon et al., 2013; Huang et al., 2017) , interferon-g (IFN-g) production (Schreiber et al., 2011; Ayers et al., 2017) , neoantigen abundance (Rizvi et al., 2015) , MHC class I expression (Marty et al., 2017; McGranahan et al., 2017) , CD28 co-stimulatory signals (Hui et al., 2017; Kamphorst et al., 2017) , patient microbiota (Matson et al., 2018; Routy et al., 2018) , and antibody composition (Arlauckas et al., 2017; Dahan et al., 2015) . However, we still have a limited understanding of how immune checkpoint blockers engage complex tumor microenvironments and which mechanisms define treatment success during the time when tumor rejection occurs. To address these knowledge gaps, we sought to track key readouts of immunotherapy function in vivo at single-cell resolution (Pittet et al., 2018) and during tumor rejection, and we decipher how immune-mediated tumor control is achieved. 
(legend continued on next page)
Considering that IFN-g and interleukin 12 (IL-12) are key immune players in tissue-specific destruction (Galon et al., 2013; Nastala et al., 1994) , we used intravital imaging to track these factors within tumors after aPD-1 treatment. Complementing singlecell imaging, we also used single-cell RNA sequencing (scRNAseq) to provide an unbiased view of immunotherapeutic responses across the tumor immune microenvironment. These approaches, further combined with manipulations of the IFN-g and IL-12 pathways in vivo, indicated that aPD-1 drove IL-12 production by a subset of tumor-infiltrating dendritic cells (DCs). Our imaging platform identified that DC activation was indirect (the drug did not detectably bind these cells in vivo) but required DC sensing of IFN-g, which was produced by aPD-1-activated T cells. In turn, IL-12 produced by DCs licensed effector T cell responses. We further report that the non-canonical nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) pathway was enriched within IL-12-producing DCs. This pathway was required for response to aPD-1, and agonizing it in a therapeutic setting enhanced IL-12 production by tumor-infiltrating DCs.
RESULTS

Successful aPD-1 Treatment Triggers Endogenous IFN-g and IL-12 Responses within Tumors
To image key readouts of immunotherapy function, we assessed IFN-g and IL-12p40, a protein subunit of IL-12 and IL-23, production using IFN-g-internal ribosome entry site-yellow fluorescent protein (IFN-g-IRES-YFP) and IL-12p40-IRES-YFP reporter mice, hereafter referred to as IFN-g-eYFP and IL-12p40-eYFP, respectively ( Figure 1A ). Intravital imaging detects YFP, which is expressed by cells that have turned on IFN-g or IL-12p40 production (Reinhardt et al., 2006 (Reinhardt et al., , 2015 . YFP remains detectable even after cytokine production is turned off, which makes intravital imaging a particularly useful tool to detect the activation of molecules with rapid on/off cycling, such as IFN-g (Slifka et al., 1999) . We tracked IFN-g and IL-12p40 in vivo during rejection of aPD-1 treatment-sensitive MC38 tumor cells, which were labeled with H2B-mApple. We also tracked macrophages, which were tagged with Pacific-blue-dextran nanoparticles (Weissleder et al., 2014) , as these cells are often abundant in tumors (Engblom et al., 2016) .
Intravital imaging of the tumor microenvironment revealed a 6.0 ± 1.1 (mean ± SEM) fold expansion of IFN-g-eYFP + cells 1 day after a single aPD-1 injection; this increase was sustained for up to 3 days after treatment ( Figures 1B and S1A ). IFN-geYFP + cells accumulated within the tumor stroma and were mostly CD8 + T cells ( Figure S1B ). Intravital imaging further revealed a 12.1-± 3.7-fold increase of IL-12p40-eYFP + cells on day 1 after treatment, which persisted for at least 5 days ( Figures  1C and S1C Figure S1D ), and parabiosis of tumorbearing mice indicated that these cells could derive from a blood-circulating precursor ( Figure S1E ). To provide a more comprehensive and unbiased view of immunotherapeutic responses across the tumor immune microenvironment, including all myeloid cell types, we performed scRNAseq analysis on CD45 + cells isolated from untreated (n = 1,154 cells sequenced)
or aPD-1-treated (n = 2,941 cells sequenced) tumors. All cells (n = 4,095) were clustered into unbiased cell type classifications using the Seurat single-cell analysis R package (Macosko et al., 2015) . The cell clusters, visualized with t-stochastic neighbor embedding (t-SNE; Figures 2A and S2A ) or force-directed graph layouts (SPRING) ( Figure S2B ; Weinreb et al., 2018) , identified the following populations: conventional T (Tconv) cells expressing Cd3e, regulatory T (Treg) cells expressing the transcription factor forkhead box P3 (Foxp3), natural killer (NK) cells expressing natural cytotoxicity triggering receptor 1(Ncr1) and killer cell lectin-like receptor subfamily B member 1c (Klrb1c), neutrophils (Neu) expressing C-X-C motif chemokine receptor 2 (Cxcr2) and G0/G1 switch 2 (G0s2), monocytes (Mo) and macrophages (Macs) expressing colony stimulating factor 1 receptor (Csf1r), and two DC subsets, referred to as DC1 and DC2. Both DC1s and DC2s expressed the DC markers Batf3, Flt3, H2-Dmb2, and Zbtb46 (Meredith et al., 2012; Hildner et al., 2008) ; DC1s expressed Fscn1 and Ly75 (DEC-205); and DC2s expressed CD209a (DC-SIGN), Mgl2 (CD301b), and Cd24a (Figures 2B and S2B) . Both DC subsets were largely negative for the (D) Representative intravital micrographs of H2B-mApple MC38 tumor edge or core obtained in IL-12p40 reporter mice before (left), 1 day after (middle), and 5 days after (right) aPD-1 treatment. PacBlue-labeled dextran was used to locate tumor vessels. Tumor cells, red; tumor-associated macrophages (TAM), blue; IL-12 + cells, green with yellow contours; tumor margin, white; blood vessels, cyan. Scale bars represent 30 mm. n.s., not significant; **p < 0.01, ****p < 0.0001. Error bar values represent SEM. Data are representative of at least two independent experiments. For comparisons between two groups, Student's two-tailed t test was used. See also Figure S1 .
macrophage colony-stimulating factor receptor Csf1r (Figure 2C ), although some DC2s expressed this receptor (Figure S2A ), similarly to a subset of intratumoral DCs previously reported (Broz et al., 2014) . DC1s had higher expression of the granulocyte/macrophage colony-stimulating factor receptor Csf2rb compared to DC2s, and neither DC1s nor DC2s expressed the granulocyte colony-stimulating factor receptor Csf3r ( Figure 2C ). Additionally, DC1s were enriched for the T cell co-stimulatory factors Cd80, Cd83, Cd86, and Icam1 (Figure 2D) , and DC1s and DC2s expressed distinct chemokines and chemokine receptors ( Figure 2E ). IL-12p40 (also known as IL12b) expression was contained exclusively within the DC1 population ( Figure 2F ). Curating genes defined from gene ontology for positive regulation of IL-12 signaling and synthesis (GO:0045084, 0032735), we found that DC1s were enriched in IL-12-related production factors such as Cd40 and Irf8 ( Figure 2G ). IL-12 + DCs in MC38 tumors did not express Itgae (the gene encoding the integrin CD103) (legend continued on next page) ( Figure S2C ), although previous studies identified CD103 + DCs as important cells for immune responses to tumors (Salmon et al., 2016; Spranger et al., 2015; Ruffell et al., 2014; Broz et al., 2014) . This discrepancy may be due to tissue location, as we found that IL-12 + DCs expressed CD103 in lung tumor models ( Figure S2D ). scRNaseq analysis confirmed the expansion of IL-12 + DCs after aPD-1 treatment ( Figure S2E ). Collectively, these data demonstrate a distinct population of IL-12-producing DCs in the tumor microenvironment.
DCs and IL-12 Are Relevant to aPD-1 Therapy To assess whether DCs are relevant to aPD-1 treatment, we generated Zbtb46-DTR bone marrow chimeras (Meredith et al., 2012) , which allowed us to deplete DCs selectively and do so after tumors were established but before aPD-1 treatment was initiated.
Mice lacking DCs failed to reject tumors in response to aPD-1 (Figure 2H) , indicating that these cells were required at the time when aPD-1-mediated tumor rejection occurs. To define whether IL-12 contributes to aPD-1 therapeutic efficacy, we studied DC-sufficient MC38 tumor-bearing mice that received aPD-1 in the presence or absence of neutralizing IL-12 mAbs. Mice in which IL-12 was neutralized failed to reject tumors, indicating that IL-12 production after aPD-1 treatment was necessary for achieving tumor control ( Figure 2I ). Collectively, these data indicate that aPD-1 treatment induces IL-12 production by DCs and that both DCs and IL-12 critically regulate aPD-1 treatment potency. The results accord with previous findings that tumor-infiltrating DCs can foster T cell immunity (Broz et al., 2014; Salmon et al., 2016) and immunotherapeutic responses (Alloatti et al., 2017) , and here we show that DCs assist antitumor responses by providing cytokine support to the tumor immune microenvironment.
IFN-g Sensing by DCs Controls IL-12 Production
To define how aPD-1 treatment activates DCs, we asked initially whether the antibody binds to these cells directly. Some myeloid cells have been proposed to express PD-1 (Gordon et al., 2017) ; however, both flow cytometry and scRNAseq analyses indicated that IL-12 + DCs did not express the PD-1 receptor at both transcript ( Figure S2A ) and protein ( Figure 3A ) levels. We further tested whether aPD-1 antibodies bind IL-12 + DCs independently of PD-1. Indeed, aPD-1 mAbs initially accumulate on PD-1 + T cells but can then be gradually taken up by tumor-associated macrophages (TAMs) in a FcgR-dependent manner (Arlauckas et al., 2017) . However, IL-12 + DCs did not express detectable levels of FcgR transcripts, in contrast to TAMs ( Figure S3A ). Also, when tracking the drug's pharmacokinetics by intravital imaging in MC38 tumor-bearing IL-12-reporter mice, we confirmed aPD-1 accumulation in TAMs but not in IL-12 + DCs 24 hr after aPD-1 administration ( Figures 3B and S3B ). The DCs also failed to bind aPD-1 early after drug administration, i.e., before uptake by TAMs ( Figure S3C ). Based on these data, we concluded that it was unlikely for aPD-1 to bind and activate IL-12 + DCs directly.
As aPD-1 mAbs physically bind to tumor-infiltrating CD8 + T cells (Arlauckas et al., 2017) , we hypothesized that these cells, once activated by aPD-1, could promote IL-12 production by DCs. To address this possibility, we used intravital imaging to track IL-12 expression in mice depleted of CD8 + T cells prior to administration of aPD-1. Absence of CD8 + T cells abrogated IL-12 production ( Figure 3C ). We further reasoned that IFN-g could mediate IL-12 production by DCs, since this cytokine was produced by aPD-1-activated CD8 + T cells ( Figure 1B) and can enhance IL-12 responses (Ma et al., 1996) . To test this hypothesis, we assessed mice in which IFN-g was neutralized during aPD-1 treatment. We found that IFN-g blockade reduced IL-12 production within the tumor microenvironment ( Figure 3D ). Decreased IL-12 production by DCs ( Figure S3D ) and decreased numbers of IL-12 + DCs (Figures S3E and S3F) both contributed to this reduction. Consequently, IFN-g blockade prevented aPD-1-mediated MC38 tumor control ( Figure S3G ). The above results suggest that IFN-g sensing by DCs fosters IL-12 production and results in tumor control. To test this hypothesis directly, we eliminated DC sensing of IFN-g by crossing Itgax-cre with Ifngr1 fl/fl mice (Lee et al., 2013) . Tumors from these mice showed impaired IL-12p40 production (Figure 3E) and were unresponsive to aPD-1 treatment ( Figure 3F ), underscoring the importance of IFN-g sensing by DCs, and potentially other CD11c-expressing cells, during aPD-1 therapy. Prior studies of Ifngr1-deficient DCs (Nirschl et al., 2017) described downregulation of genes such as Fscn1, Ccr7, and Icam1, which we identified as IL-12 + DCs distinguishers by scRNAseq analysis ( Figures 2B, 2D , and 2E). Together, we find an indirect aPD-1 effect on DCs; this effect was mediated through IFN-g and is critical for IL-12 induction and, consequently, treatment response.
IL-12 Activates Tumor-Infiltrating Lymphocyte Effector Functions in Mice
Our investigations indicated that aPD-1 treatment elicits both IFN-g and IL-12 responses at the tumor site. By contrast, we did not find evidence of IFN-g or IL-12 induction by aPD-1 in the local draining lymph node (Figures S4A and S4B) , suggesting that the checkpoint blockade response occurs within tumors. Consistent with this notion, scRNAseq data indicated that aPD-1 treatment triggered the proliferation of tumor-infiltrating CD8 + T cells ( Figure S4C ). Furthermore, blocking lymphocyte recirculation through treatment with the trafficking inhibitor FTY720 did not affect the antitumor response to aPD-1 treatment ( Figures S4D and S4E ). These data suggest that pre-existing tumor-infiltrating T cells are sufficient for driving the response to aPD-1 at least in this model. We next examined the downstream effects of IL-12 production within the tumor microenvironment. Initially we used intravital microscopy to assess the effects of recombinant IL-12 administered to tumors in IFN-g reporter mice (in the absence of aPD-1). We found that intratumoral IL-12 substantially expanded IFN-geYFP + cells (5.9-± 0.7-fold increase by day 4; Figure 4A ).
Consistent with previous reports (Nastala et al., 1994) , IL-12 administration to MC38 tumors produced robust antitumor (F) Change in MC38 tumor volume on day six after aPD-1 treatment in IFN-gR-deficient or control mice. Data are relative to pre-treatment tumor volumes. Data are representative of at least two independent experiments. n.s., not significant; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Error bar values represent SEM. For comparisons between two groups, Student's two-tailed t test was used. For comparisons between three or more groups, one-way ANOVA with multiple comparisons was used. See also Figure S3 .
responses ( Figure 4B ). To test further whether IL-12 can activate tumor-infiltrated CD8 + T cells directly, we isolated these cells from MC38 tumors and subjected them to aCD3/CD28 stimulation with or without IL-12. Stimulated CD8 + T cells substantially increased IFN-g production in the presence of IL-12 ( Figure 4C ), indicating that tumor-infiltrating T cells can respond to IL-12 directly. The requirement for both T cell co-stimulation and IL-12 to achieve maximal IFN-g response likely reflected the need of CD28 to rescue exhausted CD8 + T cells and possibly also the role of PD-1 in limiting CD28-mediated co-stimulation (Kamphorst et al., 2017; Hui et al., 2017) .
IL-12 Activates Tumor-Infiltrating Lymphocyte Effector Functions in Cancer Patients
We next addressed the downstream effects of IL-12 in cancer patients using two clinical cohorts. First, to assess IL-12's effects within tumors, we collected skin tumor biopsies from 19 melanoma patients both before and after intratumoral treatment with ImmunoPulse tavokinogene telseplasmid, an electroporation method that delivers plasmid IL-12 directly to tumors (Daud et al., 2008) . Comparison of pre-and post-treatment samples revealed that IL-12 delivery enhanced expression of core cytolytic genes (Rooney et al., 2015) within tumors (Figures 5A and 5B). These genes, namely CD2, CD3E, CD247, GZMA, GZMH, GZMK, NKG7, and PRF1, are associated with immunoediting and antitumor immune responses (Rooney et al., 2015) and tumors enriched with these genes are more likely to respond to aPD-1 immunotherapy (Riaz et al., 2017) . Accordingly, we observed a positive association between enhanced cytolytic gene signature and therapeutic response in these patients ( Figure 5C ). IFNG was not detectably increased in the post-treat- Figure S4 . ment samples, which is expected from the timing of tissue collection and rapid on/off cycling of IFN-g production by T cells (Slifka et al., 1999) . These observations indicated that IL-12 can induce cytolytic activity in human tumors.
To define whether IL-12 can directly activate human tumorinfiltrating CD8 + T cells upon isolation of these cells, we collected fresh tumor tissue from six cancer patients, which included two lung adenocarcinomas (patients BS728 and LA061), three lung squamous cell carcinomas (patients BS469, BS698, and BS705), and one synovial sarcoma (patient BS661). CD8 + T cells were purified from all tumors ex vivo ( Figure S5 ) and subjected to aCD3 stimulation with or without IL-12. The presence of IL-12 increased IFN-g production by CD8
+ T cells in five out of six patients ( Figure 5D ). Collectively, these patient data recapitulate our observations in mice that IL-12 can directly stimulate tumorinfiltrating T cell antitumor activity. They also support previous evidence that CD8 + T cell activation within tumors is critical to antitumor activity (Broz et al., 2014; Spranger et al., 2014) .
Activation of the Non-canonical NF-kB Pathway Amplifies IL-12-Producing DCs On account of IL-12's ability to license antitumor T cell immunity, we further asked whether agonizing IL-12-producing cells could augment response to aPD-1 therapy. We examined the non-canonical NF-kB pathway as a therapeutic target, considering its relevance for priming cytotoxic T cells (Katakam et al., 2015; Lind et al., 2008) and because key non-canonical NF-kB pathway genes, namely Cd40, Birc2 (Ciap1), Map3k14 (Nik), Nfkb2 (p100), and Relb, were all selectively upregulated in the IL-12 + tumor-infiltrating DC subset ( Figure 6A ). We confirmed that IL-12 + cells had more cell surface CD40 than their IL-12 -counterparts ( Figure S6A ) and that IL-12 + DCs expressed more CD40 than tumor-associated macrophages ( Figure S6B ).
We sought to activate the non-canonical NF-kB pathway in two different ways: with agonistic CD40 mAbs that have previously shown antitumor activity (Beatty et al., 2011; Byrne and Vonderheide, 2016) or with the small molecule inhibitor AZD5582 that targets cellular inhibitor of apoptosis protein (cIAP) 1 and 2 (Hennessy et al., 2013) . Agonistic aCD40 mAbs were labeled with a fluorescent dye and tracked by intravital microscopy within tumors of IL-12 reporter mice. This imaging approach not only showed the drug's ability to interact directly with IL-12 + tumor-infiltrating cells, and some macrophages, in vivo ( Figure 6B ) but further identified that the treatment induced a 6.6-± 1.2-fold increase of tumor-infiltrating IL-12 + cells ( Figure 6C ). Flow cytometry measurements indicated that IL-12 was produced by DCs but not TAMs (Figures 6D and 6E ). These findings align with previous evidence that aCD40 therapy relies upon Batf3-dependent DCs (Byrne and Vonderheide, 2016) , although macrophages can also contribute to aCD40 therapy in some settings, which may be independent of IL-12 (Hoves et al., 2018; Beatty et al., 2011) . CD40, in addition to activating myeloid cells, is also a wellknown activator of B cells. Therefore, we tested whether B cells were important for aCD40 therapy response. We found that B cell depletion had no effect on aCD40 therapy, suggesting that B cells are not necessary for aCD40 treatment in this experimental model (data not shown).
Treating tumors with the cIAP antagonist AZD5582 induced a 4.0-± 1.3-fold increase of IL-12 + tumor-infiltrating cells (Figure 6C) , similar to the effects observed with agonistic CD40 mAbs. Furthermore, stimulation of Flt3L-derived bone marrow DCs with AZD5582 potently enhanced IL-12 production in vitro n.s., not significant; ND, not detected; *p < 0.05, **p < 0.01, ***p < 0.001. Error bar values represent SEM. For comparisons between two groups, Student's twotailed t test was used. See also Figure S5 .
( Figure S6C ). These results not only confirm previous evidence that CD40 agonism is a stimulatory signal for DCs (Cella et al., 1996; Ngiow et al., 2016) but also indicate that triggering the non-canonical NF-kB pathway, through CD40 agonism or cIAP inhibition, can amplify IL-12 + tumor-infiltrating DCs.
Amplification of IL-12 + DCs Improves Cancer Immunotherapy in an IL-12-Dependent Manner The antitumor activity of agonistic CD40 mAbs (aCD40) has been shown to depend upon IFN-g (Byrne and Vonderheide, 2016) . We evaluated aCD40 in IFN-g reporter animals and indeed found that aCD40 treatment potently enhanced intratumoral IFN-g levels ( Figure 7A ). The IFN-g induction by aCD40 likely occurred indirectly as T cells did not express CD40 ( Figure 6A ). Furthermore, treatment with either agonistic aCD40 mAbs or AZD5582 provided antitumor effects in vivo ( Figure 7B ). To test the relevance of IL-12 after treatments with aCD40 or AZD5582, we compared their effects in MC38 tumor-bearing mice that were administered or not with IL-12 neutralizing mAbs. These studies showed that IL-12 induction was a primary mechanism for these treatments because tumor control was lost in animals receiving IL-12 neutralizing mAbs ( Figure 7B ). To further assess the requirement of non-canonical NF-kB signaling to aPD-1 treatment efficacy, we compared aPD-1 responses in mice that were reconstituted with either Map3k14 (NIK)-deficient or wild-type bone marrow. NIK chimeras failed to respond to aPD-1 ( Figure S7A ). Taken together, these data linked the noncanonical NF-kB pathway to antitumor intratumoral DCs and to aPD-1 treatment efficacy and indicated that targeting non-canonical NF-kB components can be therapeutic in cancer.
Next we defined whether agonizing IL-12 + cells could augment response to aPD-1 therapy. To this end, we assessed MC38 tumor progression in mice treated with antagonist aPD-1, agonist aCD40, or both. We found that monotherapies incompletely controlled tumor growth, whereas the combination treatment produced a complete, durable response in most animals treated ( Figures 7C, S7B , and S7C). Mice that received combination treatment further resisted tumor re-challenge 8 weeks after the primary tumor rejection ( Figure S7D) ; this indicated that the treatment had triggered antitumor memory. (E) MFI of IL-12 reporter signal from TAM or DC. Data are representative of at least two independent experiments. n.s., not significant; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; one-way ANOVA with multiple comparisons. Error bar values represent SEM. See also Figure S6 .
Because the MC38 tumor model responds--though not completely--to aPD-1 monotherapy, we also tested the B16F10 melanoma model, which resists aPD-1 treatment. We found that combining aPD-1 with aCD40 mAbs controlled B16F10 tumor growth ( Figures S7E and S7F ) and resulted in increased mouse survival ( Figure 7D) , when compared to aPD-1 or aCD40 monotherapies. The combination treatment rejected tumors in 50% (6 of 12) mice; these mice resisted secondary tumor challenge ( Figure 7E ), indicating that the treatment had also triggered antitumor memory in this model.
Considering that recombinant IL-12 administered to B16F10 melanoma-bearing mice also produced a substantial antitumor effect ( Figure 7F ), we tested whether the aPD-1+aCD40 therapeutic combination relied upon IL-12 for activity. We administered the combination immunotherapy to B16F10-bearing mice in the presence or absence of IL-12 neutralizing mAbs and found that blocking IL-12 signaling prevented the combination treatment's therapeutic activity ( Figures 7G and S7G ). These data indicate that DC targeting can augment immunotherapy efficacy and sensitize tumors to aPD-1 treatment in an IL-12-dependent manner.
DISCUSSION
We used single-cell resolution readouts, including intravital microscopy and scRNAseq, to discover cancer immunotherapy pharmacodynamics within tumors and better define in vivo mechanisms of tumor rejection. We found that the antitumor cytokines IFN-g and IL-12 were mutually induced by immunotherapy and further distinguished direct and indirect mechanisms of activation for these respective cytokines. Principally, we identified that aPD-1 directly induced IFN-g production by activated T cells, but indirectly induced IL-12 production by a subset of intratumoral DCs. IL-12 production required DC Untreated mice served as controls (gray circles), n R 5 mice/group. Data are representative of at least two independent experiments. n.s., not significant; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Error bar values represent SEM. For comparisons between two groups, Student's two-tailed t test was used. For comparisons between three or more groups, one-way ANOVA with multiple comparisons was used. See also Figure S7. sensing of IFN-g, and, in turn, licensed effector T cell responses in both mice and cancer patients. We also showed that IL-12-producing DCs were enriched for non-canonical NF-kB signaling pathway components, that the critical non-canonical NF-kB kinase NIK was required for aPD-1 response, and that agonism of the non-canonical NF-kB pathway in a therapeutic setting produced an IL-12-dependent antitumor response. Furthermore, triggering the T cell:DC crosstalk through non-canonical NF-kB agonism in combination with aPD1 treatment could potently enhance antitumor immunity. These data support an IL-12-driven ''licensing'' model of aPD-1 therapy, in which aPD-1 mAb targeting of T cells leads to tumor elimination only after successful crosstalk between these T cells and DCs. We suggest further that responses to immunotherapy can be improved through rational drug combinations that accentuate the crosstalk between lymphoid and myeloid immune compartments.
Real-time in vivo imaging allows one to identify not only primary targets of immunotherapeutics (drug pharmacokinetics) (Arlauckas et al., 2017) but also how the tumor microenvironment responds to treatment (drug pharmacodynamics). Consequently, this type of imaging complements the use of gene-deficient mouse models to study cancer treatments: whereas genedeficient models can establish the relevance of particular genes in immunotherapy, imaging provides molecular dynamics at single-cell and spatial resolutions and over a longitudinal course of therapeutic response. Caveats still exist with this imaging approach, however, as distribution and effector functions of antibodies may differ between species and antibody compositions. It is also worth noting that the investigations presented in this study used cytokine reporter animals for readout of immune cells' functional attributes, as opposed to immune cells' identities. We believe this is important because antitumor immune functions may not necessarily be cell type dependent, so in theory different cell types can be imaged but the functional readout still remains. For example, in the experimental setups used in this study, we found that CD8 + T cells and DCs are the primary producers of IFN-g and IL-12, respectively; however, under different experimental contexts it is possible that NK cells may also produce IFN-g and macrophages may also produce IL-12. It should also be noted that the present report focuses on pharmacodynamic imaging of aPD-1 and aCD40, although our imaging platform can in principle be used to interrogate any immune drug or other therapeutic agent, and further be expanded to additional functional readouts. There is increasing support for DCs taking a center stage in checkpoint immunotherapies in cancer. In particular, the cDC1 subtype of DCs, which resembles the DC1 subtype presented here, is adept at cross-presenting antigens (Schlitzer and Ginhoux, 2014 ) and appears essential for T cell-driven antitumor immunity (Hildner et al., 2008) . Interestingly, these DCs may be involved at different stages during the tumor rejection process: besides their critical role for priming T cells in lymph nodes (MartIn-Fontecha et al., 2003) , recent studies demonstrated that DCs can be found in tumors, where they recruit T cells and stimulate tumor-reactive T cell responses locally (Spranger et al., 2014; de Mingo Pulido et al., 2018) . The findings presented here align with the notion that intratumoral DCs can exhibit key antitumor functions and promote aPD-1 immunotherapy. Systemic involvement of immunotherapy responses could also be relevant. For example, in the context of a longer duration of response, it is possible that aPD-1's antitumor activity is promoted initially by intratumoral DCs and T cells, and later by an additional pool of cells that are recruited from outside the tumor microenvironment (perhaps from the bone marrow or even from tumor-draining lymph nodes).
We found that IL-12 + DCs do not always express the marker CD103 (encoded by Itgae), which is often used to define antitumor DCs. It is possible that CD103 is not required for DCs' antitumor functions and that its expression depends at least in part on the tissue where the DCs reside. In contrast, IL-12 may be both a marker and functional feature of immunostimulatory tumor DCs, based on our findings that (1) IL-12 + DCs share many features with cross-presenting DC1 cells, including expression of Batf3, Irf8, Flt3, and Ly75 (DEC205), and (2) IL-12 is required for immunotherapy efficacy. This notion further accords with prior evidence that cross-presenting tumor DCs have elevated IL-12 expression (Broz et al., 2014; Ruffell et al., 2014) . Our data further indicate that IL-12-producing DCs can be generated by circulating precursors, although future studies should aim to precisely determine the ontogeny of these cells. The findings presented here show that IL-12 cytokine signals supplied by intratumoral DCs assist antitumor immunity. It will be interesting to further investigate the interactions between IL-12 + DCs, IFN-g + T cells, and immunotherapeutics. For example, considering that DCs can express PD-L1 and that PD-1 is activated upon binding to PD-L1, it should be helpful to elucidate the function and fate of PD-L1 expressed by intratumoral DCs after aPD(L)1 treatment. Also, since IL-12 + DCs express the highest levels of CD28's co-stimulatory ligands, CD80 and CD86, it is possible that these ligands contribute to an aPD-(L)1 antitumor response. Furthermore, IL-12 produced by intratumoral DCs may mediate antitumor effects through regulation of transcription factors such as T-bet and Eomes in effector T cells. Indeed, IL-12 may activate T-bet (Joshi et al., 2007; Szabo et al., 2000) and in doing so subvert exhaustion phenotypes (Kao et al., 2011) . IL-12 may also repress Eomes (Takemoto et al., 2006) , which is a major regulator of T cell exhaustion (Paley et al., 2012) . Further study of cells responding to IL-12 could define additional avenues to reverse T cell exhaustion and potentiate antitumor immunity. By looking at direct versus indirect effects of immunotherapy in the tumor microenvironment, we can start to better understand the mechanisms of tumor rejection in vivo, and, by extension, to rationally design combination therapeutic strategies. Here, we initially used the MC38 mouse tumor model because it is sensitive to aPD-1 treatment and thus is relevant to define mechanisms dictating treatment success. Furthermore, recapitulation of IFN-g/IL-12-positive feedback mechanisms, through combination therapy, enables tumor control in harder-to-treat cancer models. Specifically, our analysis demonstrated that activating the non-canonical NF-kB pathway in intratumoral DCs through either CD40 agonism or cIAP inhibition can potently enhance aPD-1-mediated tumor control.
Treatments combining CD40 agonists with PD-1 pathway inhibitors (Clinicaltrials.gov: NCT03123783, NCT02376699) and cIAP inhibitors with aPD-L1 (Clinicaltrials.gov: NCT03270176) are currently in clinical trials. We suggest that both treatment strategies may rely upon the non-canonical NF-kB pathway and DCs. Further, since our studies indicated that non-canonical NF-kB-targeting drugs depend upon IL-12 for mediating antitumor activity, we speculate that introduction of IL-12 could potently enhance aPD-1 immunotherapy. Previous attempts to develop IL-12-based therapies for human use had severely toxic consequences (Lasek et al., 2014) likely due to systemic administration routes. However, targeted intratumoral delivery of IL-12-encoding plasmids is safe and has already demonstrated antitumor efficacy as monotherapy (Daud et al., 2008) . We suggest that further clinical studies should test whether rationally designed therapeutic strategies that accentuate T cell:DC crosstalk can enforce tumor-eliminating positive feedback mechanisms and expand the proportion of cancers sensitive to immunotherapy.
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Single Cell RNA Sequencing MC38 tumors were implanted into the flanks of C57BL6/J mice and allowed to grow for 7 days before immunotherapy treatment. Mice were untreated or aPD-1 treated. Tumors were harvested 3 days after initiation of therapy. Tumors were digested using collagenase II (Worthington) and CD45 + cells were sorted from single cell suspensions using a BD FACSAria sorter. Cells were manually counted with a hemocytometer and trypan blue viability stain, and 3132 cells from the control treated and 8178 cells from the aPD-1 treated tumors were recovered directly in PBS with 0.04% BSA (400 mg/ml) without centrifugation and kept on ice. Live cells were single cell sorted into GEMS (Gel Bead in EMulsion) using the 10X Genomics Chromium system provided by the HMS Biopolymers core. GEMS were processed and libraries were prepared according to the Chromium Single Cell 3 0 Reagent Kit v2 User guide (10X Genomics). Library QC was done by the HMS Biopolymers core and the libraries were sequenced on an Illlumina NextSeq at an average of 29,000 reads per cell. In total, 4095 cells (1154 untreated and 2941 aPD-1 treated cells) passed QC and were sequenced. 10X Cell Ranger 2.1.0 software was used for generation of fastq files and gene-barcode matrices. Loupe Cell Browser 2.0.0 and the Seurat R package and SPRING (Weinreb et al., 2018) were used for clustering and analysis. Gene ontology analysis was performed using the DAVID Bioinformatics Resource v.6.8.
Parabiosis
CD45.3 and B6.129-Il12btm1Lky/J (IL-12 reporter) mice were placed under anesthesia (2% isoflurane) shaved on their sides and elbows and knees were stitched together with a black monofilament nylon suture (Ethicon). Animals were provided with buprenorphine as an analgesic for 3 days following surgery. After a 3 week recovery period, both mice from the parabiotic pair were challenged with MC38 tumors on the outer flank. Tumors were allowed to grow for 7 days before treatment with aPD-1 immunotherapy, and tumors were harvested 2 days following immunotherapy to analyze IL-12 dendritic cell populations by flow cytometry.
FTY 720 Treatments
Mice were implanted with MC38 tumors in the flank and cohorts of mice were sorted into groups of similar tumor size before treatment initiation. Tumors were allowed to grow for 7 days before treatments. Mice were treated or not with 1.25 mg/kg of FTY720 (Cayman Chemical) i.p. 2 hours before aPD-1 treatment, and were maintained daily on 1.25 mg/kg FTY720 throughout the duration of the experiment. Blood from mice was used to confirm lymphocyte trafficking defects.
Flow Cytometry -Mouse
Tumor tissue or tumor draining lymph nodes were isolated from mice and minced using surgical scissors. Tissues were then digested using 0.2 mg/ml Collagenase II (Worthington) in RPMI 1640 media (CellGro) at 37 C for 30 minutes and then strained through a 40 mm filter (BD Falcon). Cell suspensions were incubated with Fc Block TruStain FcX Clone 93 (Biolegend) in PBS containing 0.5% BSA and 2 mM EDTA before staining with fluorochrome labeled antibodies. Antibodies against CD11b (M1/70, Biolegend), CD8a (53-6.7, Biolegend), CD45 (30-F11, BD), F4/80 (BM8, Biolegend), CD11c (N418, Biolegend), MHC II I-A/I-E (M5/114.15.2, Biolegend), CD103 (2E7, Biolegend), IFN-g (XMG1.2, Biolegend) were used for marker staining. 7AAD viability staining was used to exclude dead cells from analysis. Samples were run on a LSR II flow cytometer and analyzed using FlowJo software (Treestar). For intracellular cytokine staining, samples were incubated for 5 hours with GolgiPlug (BD) at 1 ml per ml of culture media. Cells were then surface stained and then fixed and permeabilized using the BD Cytofix/Cytoperm kit (BD) according to manufacturer's protocol and stained for intracellular cytokines.
Intravital Imaging
Interferon gamma reporter (IFN-g-eYFP) or IL-12p40 reporter (IL12p40-eYFP) mice were anesthetized and dorsal skin-fold window chambers were installed as previously described (Thurber et al., 2013) and mice were treated with analgesic (Buprenorphine 0.1 mg/kg/day) for 3 days following chamber implantation. Twenty-four hours after window implantation, MC38-H2B-mApple cells (2 3 10 6 in 20 ml) were injected in the fascia layer. Pacific Blue-dextran nanoparticle (containing 1 nmol Pacific Blue dye) was injected 1 week after tumor implantation for macrophage labeling. On the next day, Pacific Blue-dextran (containing 37 mg dextran and 56 nmol Pacific Blue dye) for vascular labeling was delivered via a 30-gauge catheter inserted in the tail vein of the anesthetized mouse (2% isoflurane in oxygen). Anesthetized mice were kept on a heating pad kept at 37 C, vital signs monitored and mice were imaged using an Olympus FluoView FV1000MPE confocal imaging system (Olympus America). A 2x air objective XL Fluor 2x/340 (NA 0.14; Olympus America) was used to select regions near tumor margins and tumor vasculature by an operator blinded to treatment conditions. Higher magnification Z stack images were acquired using a XLUMPLFL 20 3 water immersion objective (NA 0.95; Olympus America) with 1.5x digital zoom. Sequential scanning (5 mm slices) with 405, 473, 559, and 635 nm lasers was performed using voltage and power settings that were optimized using fluorescence minus-one control mice prior to time lapse acquisition. DM405/473/559/635 nm dichroic beam splitters (SDM473, SDM560, and SDM 640) and emission filters (BA430-455, BA490-540, BA575-620, BA575-675) were sourced from Olympus America. For time lapse acquisitions, a total frame interval of 133 s was acquired at non-overlapping coordinates. For CD8+ cell depletions, 200 mg of aCD8 was delivered 24 hours prior to aPD-1. Unlabeled antibodies were used with the exception of specific cases where AF647-aPD-1 mAb or AF647-aCD40-mAb were delivered for drug distribution studies. Fluorochrome labeled antibodies were delivered at the same dose as unlabeled antibodies.
Isolation of Tumor-Infiltrating Lymphocytes and in vitro Restimulation MC38 tumors were digested into single cell suspensions similar to tissue processing for flow cytometry analysis and were passed through a 40 mm filter. Cells were then labeled using the Miltenyi CD8a T cells enrichment kit (Miltenyi Biotec) and isolated using magnetic sorting according to manufacturer's protocols. Tissue culture plates were coated with anti-CD3ε and anti-CD28 at a concentration of 10 mg/ml and 5 mg/ml respectively in PBS for 12 hours, and excess antibody was aspirated before T cell addition. IL-12 was added into culture media at a concentration of 20 ng/ml. Cells were stimulated for 72 hours before addition of GolgiPlug for 5 hours for intracellular cytokine staining Tissue Isolation and Quantitative PCR Fresh MC38 tumor tissue (20-30 mg) from WT C57BL6/J aPD-1 treated mice, WT C57BL6/J aPD-1/aIFN-g treated mice, aPD-1 treated Ifngr1 fl/fl mice, or aPD-1 treated Cd11c-cre Ifngr1 fl/fl mice, were finely minced using surgical scissors and lysed in RLT lysis buffer (QIAGEN) and frozen. Samples were then thawed and RNA was extracted using the QIAGEN Mini RNA extraction kit, and reverse transcribed using the High-Capacity cDNA kit (Thermo Fisher Scientific). Quantitative PCR was performed using Il12p40 Taqman Gene Expression probes (Thermo Fisher Scientific) and referenced to HPRT expression using 10 ng of cDNA per sample. The DDCT method was used to quantitate Il12p40 expression across samples. eBioscience), CD11c PerCP eFluor710 (clone 3.9, eBioscience); CD14 PerCP-eFluor710 (clone 61D3, Biolegend); CD19 PerCPCy5.5 (clone SJ25C1, Biolegend); CD45 APC-H7 (clone 2D1, BD PharMingen); CD56 APC (clone AF12-7H3, Miltenyi).
QUANTIFICATION AND STATISTICAL ANALYSIS
Image Processing Images were Z-projected, cropped, and de-speckled for clarity using FIJI running ImageJ version 2 (6). For quantification, raw Z stack images were processed using rolling ball background subtraction, Renyi Entropy thresholding, and cell counting macros run through customized Java scripts in the FIJI environment. TAM and tumor vessels were segmented by pixel size and shape exclusion parameters. Cell number divided by area were reported relative to baseline prior to treatment. The Manual Tracking Plugin was used in FIJI for cell tracking. The slope of the regression function fitted to the mean displacement plot for each cell calculated to derive the cell motility coefficients (M), according to the following formula: M = d2 / 4t, where d is displacement from origin at time t.
Statistical analysis
Flow and imaging data were collected using FlowJo Version 10.4 and the FIJI package of ImageJ running version 1.51 s. This and other primary data was collected and organized using Microsoft Excel (version 14.6.3). All statistical analyses were performed using Graphpad Prism Version 7. Mouse cohort sizes were pre-determined using power analyses, as reported previously (Arlauckas et al., 2017) . Values reported in figures are expressed as the standard error of the mean, unless otherwise indicated. For normally-distributed datasets, we used 2-tailed Student's t test and one-way ANOVA followed by Bonferroni's multiple comparison test. When variables were not normally distributed, we performed non-parametric Mann-Whitney or Kuskal-Wallis tests. For survival analysis, p values were computed using the Log Rank test. p values > 0.05 were considered not significant (n.s.), p values < 0.05 were considered significant. * p value < 0.05, ** p value < 0.01, *** p value < 0.001, **** p value < 0.0001.
DATA AND SOFTWARE AVAILABILITY
Raw data for single cell RNA sequencing from sorted CD45+ cell populations from MC38 tumors can be found at the Gene Expression Omnibus Repository (GEO). The accession number for control (untreated) samples is GSM3090155. The accession number for aPD-1-treated samples is GSM3090156.
